Introduction
EQT is a leading global investment organization headquartered in Stockholm, Sweden, with a strong focus on active ownership and sustainable value creation. Founded in 1994, EQT has grown into one of the world’s largest private equity firms, managing over €100 billion in assets under management as of 2026. The firm operates across multiple sectors, including private capital, real assets, and infrastructure, emphasizing long-term growth and impact-driven strategies. Within this framework, EQT Life Sciences represents a specialized division dedicated to healthcare and biotechnology investments, while Anticimex, a portfolio company under EQT’s ownership, exemplifies the firm’s approach to scaling businesses in essential services like pest control.
The concept of EQT Life Sciences / Anticimex 收購策略 refers to the acquisition strategies employed by these entities under the EQT umbrella. This strategy encompasses targeted buyouts, add-on acquisitions, and growth investments aimed at fostering innovation, expanding market presence, and enhancing operational efficiency. By examining EQT Life Sciences / Anticimex 收購策略, we can understand how EQT leverages mergers and acquisitions (M&A) to build resilient, high-growth companies. In this article, we delve into the details of these strategies, highlighting their evolution, key examples, and future implications.
Overview of EQT Life Sciences
EQT Life Sciences, formerly known as Life Sciences Partners (LSP), was integrated into EQT in 2021 through an acquisition valued at approximately €450 million. This move strengthened EQT’s position in the healthcare sector, combining LSP’s 30-year track record in life sciences venture capital with EQT’s global resources. As of 2026, EQT Life Sciences has raised around €3.5 billion across 12 funds and manages investments in over 150 private companies. The division focuses on subsectors such as biotechnology, medical devices, and digital health, with a mission to back inventors whose ideas can improve patient outcomes.
The team’s composition is a key strength: over 65 investment professionals with backgrounds in medicine, science, and industry. This expertise enables EQT Life Sciences to identify and nurture high-potential opportunities in Europe and beyond. Recent activities include co-leading funding rounds and strategic buyouts, reflecting a proactive approach to portfolio building.
The Acquisition Strategy of EQT Life Sciences
At the core of EQT Life Sciences / Anticimex 收購策略 is a focus on innovative, fast-growing companies that address unmet needs in healthcare. Unlike traditional private equity, EQT Life Sciences employs a blend of venture capital and growth buyout strategies. For instance, in 2024, EQT introduced the Healthcare Growth Strategy, a dedicated buyout approach that targets scaling proven healthcare firms. The first investment under this strategy was Mabtech, a life sciences tools company acquired from the IK Small Cap II Fund, demonstrating EQT’s emphasis on acquiring assets with strong technological foundations.
This strategy prioritizes companies in Europe but extends globally, investing in areas like RNA therapeutics and dementia treatments. A notable example is the 2026 Series A financing of Aerska, where EQT Life Sciences co-led a $39 million round to advance brain shuttle technology for RNA medicines. Such investments often involve co-investing with partners like age1 and laso Ventures, reducing risk while amplifying impact.
EQT Life Sciences also facilitates exits through acquisitions by larger players. In 2025, portfolio company Merus was acquired by Genmab for $8 billion, and ImCheck Therapeutics by Ipsen for up to €1 billion. These deals underscore the strategy’s success in building value, with a focus on long-term support beyond capital—including board-level guidance and operational expertise. The approach aligns with EQT’s broader sustainability goals, ensuring investments contribute to positive healthcare outcomes.
In essence, EQT Life Sciences / Anticimex 收購策略 in the life sciences domain is characterized by targeted, impact-oriented acquisitions that leverage scientific innovation for commercial scalability. This has positioned EQT as one of Europe’s largest life sciences investors, with a portfolio that continues to drive advancements in biotechnology and medicine.
Overview of Anticimex
Anticimex, founded in 1934 in Sweden, has evolved from a local pest control provider to a global leader serving over three million customers in 21 countries. The company specializes in preventive pest control, emphasizing digital solutions like SMART technology—a sensor-based system that monitors infestations in real-time, reducing pesticide use and promoting sustainability.
EQT first acquired Anticimex in 2012 through its EQT VI fund, transforming it from a Nordic player into an international powerhouse. By 2021, EQT transitioned ownership to its new longer-hold fund, EQT Future, in a deal valuing the company at SEK 60 billion (approximately $7.2 billion including debt). This move involved co-investors like Melker Schörling AB, GIC, and AMF, highlighting EQT’s strategy of partnering with long-term stakeholders.
Under EQT’s stewardship, Anticimex achieved remarkable growth: 19% compound annual revenue growth and 29% EBITA growth from 2011 to 2020. The company’s expansion into markets like the US, Europe, and Asia-Pacific has been fueled by a robust M&A pipeline, making it a prime example of EQT’s value creation model.
The Acquisition Strategy of Anticimex
Anticimex’s acquisition strategy is a cornerstone of EQT Life Sciences / Anticimex 收購策略, designed to enhance geographic reach, customer density, and service offerings. Since EQT’s initial investment, Anticimex has completed over 400 add-on acquisitions, averaging 40-50 deals annually. This roll-up approach targets local pest control firms that align with Anticimex’s operational model, integrating them to boost efficiency along existing routes.
The process is streamlined into three steps: Origination (identifying fits through informal meetings), Execution (2-4 months of due diligence and documentation), and Integration (seamless onboarding with cultural alignment). Recent examples include the 2025 entry into Texas via acquisitions of SafeHaven Pest Control, Abby’s Pest & Termite Services, and Metro Guard Termite and Pest Control. These moves not only expanded Anticimex’s footprint but also leveraged synergies in digital pest prevention.
Sustainability is integral: Acquisitions prioritize companies that can adopt SMART technology, reducing environmental impact. This aligns with EQT’s longer-hold philosophy, shifting from financial engineering to sustained value creation. As a result, Anticimex has grown 80x under private equity ownership, with the majority under EQT.
Comparing EQT Life Sciences and Anticimex Strategies
While EQT Life Sciences / Anticimex 收購策略 share EQT’s active ownership ethos, they differ in focus. EQT Life Sciences emphasizes innovation-driven buyouts in high-tech healthcare, often involving early-stage ventures and strategic exits. In contrast, Anticimex’s strategy is more acquisitive, focusing on consolidating fragmented markets through bolt-on deals.
Both, however, prioritize impact: Life Sciences advances patient care, while Anticimex promotes public health by curbing pest-borne diseases and food waste. EQT’s integration of these approaches demonstrates a versatile M&A framework adaptable to diverse sectors.
Future Outlook and Implications
Looking ahead, EQT Life Sciences / Anticimex 收購策略 are poised for further evolution amid global challenges like climate change and healthcare demands. EQT Life Sciences may expand into emerging fields like AI-driven diagnostics, while Anticimex could accelerate digital adoption in new markets. With EQT’s commitment to longer-hold investments, these strategies will likely yield sustained growth and societal benefits.
In summary, EQT Life Sciences / Anticimex 收購策略 exemplify EQT’s prowess in transforming businesses through strategic acquisitions, blending financial acumen with purpose-driven goals.
FAQ
What does “EQT Life Sciences / Anticimex 收購策略” mean?
It refers to the acquisition strategies of EQT Life Sciences, a healthcare investment arm of EQT, and Anticimex, a pest control company owned by EQT. The term combines their approaches to M&A in Chinese (“收購策略” means “acquisition strategy”).
How has EQT influenced Anticimex’s growth?
EQT acquired Anticimex in 2012 and transitioned it to a longer-hold fund in 2021. Under EQT, Anticimex has executed over 400 acquisitions, expanding to 21 countries and achieving significant revenue growth through operational improvements and digital innovation.
What is the focus of EQT Life Sciences’ investments?
EQT Life Sciences targets innovative healthcare companies in biotechnology, medical devices, and digital health. It uses venture and growth strategies to fund and scale firms that improve patient outcomes, with recent examples including investments in RNA therapeutics and acquisitions like Mabtech.
How many acquisitions has Anticimex made recently?
As of 2026, Anticimex has completed 18 acquisitions in the last few years, with a focus on the US market, including three in Texas in 2025 to enter new regions.
What makes EQT’s acquisition strategies sustainable?
Both entities emphasize impact: EQT Life Sciences supports health advancements, while Anticimex promotes pesticide-free solutions. EQT’s longer-hold approach prioritizes long-term value over quick exits, aligning with global sustainability goals.
Can individuals invest in EQT Life Sciences or Anticimex?
EQT is a private equity firm, so direct investments are typically for institutional investors. However, EQT AB is publicly traded on the Nasdaq Stockholm, allowing indirect exposure through shares.
